Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) Enterprise Value (2016 - 2025)

Veracyte's Enterprise Value history spans 14 years, with the latest figure at -$362.6 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 51.65% year-over-year to -$362.6 million; the TTM value through Dec 2025 reached -$362.6 million, down 51.65%, while the annual FY2025 figure was -$362.6 million, 51.65% down from the prior year.
  • Enterprise Value for Q4 2025 was -$362.6 million at Veracyte, down from -$315.6 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$153.4 million in Q2 2022 and bottomed at -$362.6 million in Q4 2025.
  • The 5-year median for Enterprise Value is -$205.8 million (2023), against an average of -$223.0 million.
  • The largest annual shift saw Enterprise Value tumbled 122.14% in 2021 before it skyrocketed 53.15% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$173.2 million in 2021, then grew by 10.94% to -$154.2 million in 2022, then plummeted by 40.33% to -$216.5 million in 2023, then dropped by 10.46% to -$239.1 million in 2024, then tumbled by 51.65% to -$362.6 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Enterprise Value are -$362.6 million (Q4 2025), -$315.6 million (Q3 2025), and -$219.5 million (Q2 2025).